Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713609 | 0.87 | CYP4F2 (0.31) | RETCYP4F2CYP4A11 | |
| SCHEMBL31190804 | 0.85 | CYP4F2 (0.33) | RETCYP4F2CYP4A11 | |
| SCHEMBL27187913 | 0.83 | CYP4F2 (0.36) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL30540775 | 0.79 | RET (0.32) | RETCYP4F2CYP4A11 | |
| SCHEMBL30540754 | 0.76 | EGFR (0.37) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL298676 | 0.76 | CYP4F2 (0.36) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL16100337 | 0.76 | CYP4F2 (0.36) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL29712202 | 0.76 | CYP4F2 (0.34) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL24607090 | 0.76 | CYP4F2 (0.34) | ATRRETCYP4F2CYP4A11 | |
| SCHEMBL31327357 | 0.76 | CYP4F2 (0.34) | ATRRETCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4271673-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | Tyra Biosciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116761798-A | Indazoles as kinase inhibitors | 泰拉生物科学公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022147246-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147246-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | ATR 828/4885RET 47/4885CYP4F2 1846/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ATR 828/4885RET 47/4885CYP4F2 1846/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ATR 828/4885RET 47/4885CYP4F2 1846/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | ATR 828/4885RET 47/4885CYP4F2 1846/4885 |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ATR 828/4885RET 47/4885CYP4F2 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.